PTEN and glioblastoma: Genomic and transcriptomic analysis correlated with the patients’ response to immunotherapy: those who did not respond showed mutations in PTEN that are associated with immunosuppressive expression signatures, whereas responders carried mutations in components of the mitogen-activated protein kinase (MAPK) pathway.100 These results demonstrate that the response to immunotherapy by using PD-1 inhibitor varies according to specific molecular alterations, and the therapy may benefit a subgroup of GBM patients, suggesting a molecular and personalised selection of patients for immunotherapies.